Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2024-11-19 DOI:10.1002/cam4.70410

Yuhan Liu, Yuhan Zou, Yangli Ye, Yong Chen

{"title":"Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer","authors":"Yuhan Liu, Yuhan Zou, Yangli Ye, Yong Chen","doi":"10.1002/cam4.70410","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by high aggressiveness, high malignancy, and poor prognosis compared to other breast cancer subtypes.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>This review aims to explore recent advances in understanding TNBC and to provide new insights and potential references for clinical treatment.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We examined current literature on TNBC to analyze molecular subtypes, genetic mutations, signaling pathways, mechanisms of drug resistance, and emerging therapies.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Findings highlight key aspects of TNBC's molecular subtypes, relevant mutations, and pathways, alongside emerging treatments that target drug resistance mechanisms.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These insights into TNBC pathogenesis may help guide future therapeutic strategies and improve clinical outcomes for patients with TNBC.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 22","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70410","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70410","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by high aggressiveness, high malignancy, and poor prognosis compared to other breast cancer subtypes.

Objective

This review aims to explore recent advances in understanding TNBC and to provide new insights and potential references for clinical treatment.

Methods

We examined current literature on TNBC to analyze molecular subtypes, genetic mutations, signaling pathways, mechanisms of drug resistance, and emerging therapies.

Results

Findings highlight key aspects of TNBC's molecular subtypes, relevant mutations, and pathways, alongside emerging treatments that target drug resistance mechanisms.

Conclusion

These insights into TNBC pathogenesis may help guide future therapeutic strategies and improve clinical outcomes for patients with TNBC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

了解三阴性乳腺癌发病机制的进展。

背景：三阴性乳腺癌（TNBC）是一种异质性疾病：三阴性乳腺癌（TNBC）是一种异质性疾病，与其他乳腺癌亚型相比，其特点是侵袭性强、恶性程度高、预后差：本综述旨在探讨了解 TNBC 的最新进展，并为临床治疗提供新的见解和潜在参考：我们研究了当前有关 TNBC 的文献，分析了分子亚型、基因突变、信号通路、耐药机制和新兴疗法：结果：研究结果强调了 TNBC 分子亚型、相关突变和通路的关键方面，以及针对耐药机制的新兴疗法：结论：对 TNBC 发病机制的这些认识有助于指导未来的治疗策略，改善 TNBC 患者的临床疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.